Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Yogurt power: probiotics may ease fatigue in MS patients

NCT ID NCT07346924

Symptom relief Sponsor: Cairo University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether adding probiotics (found in yogurt and yeast tablets) to standard therapy could improve fatigue, quality of life, mood, and inflammation in 60 people with relapsing-remitting multiple sclerosis. Participants were randomly assigned to take probiotics or not, and researchers tracked changes using fatigue scales and inflammatory markers. The goal was to see if tweaking gut bacteria could offer extra benefits for managing MS symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Probiotic dietary supplement (yogurt with Bifidobacterium and Lactobacillus strains, plus yeast tablets)
What this could lead to
If it works, this could point toward a simple, low-cost way to help manage fatigue and improve quality of life in people with relapsing-remitting MS.
What could go wrong
This is a small, completed study in Egypt, so results may not apply to other populations. Probiotics are generally safe but may not provide meaningful benefit for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

Jan 2024

Finished

Mar 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Clinically definite MS patients with a diagnosis of relapsing remitting multiple sclerosis according to revised McDonald criteria 2017. * EDSS score of ≤ 4 Exclusion Criteria: * Progressive MS either; primary progressive MS or secondary progressive MS * Patients who had relapses and glucocorticoid therapy within the past 30 days. * Pregnancy and women who were lactating within the prior six month * Patients taking antibiotics * History of gastroenteritis and bowel surgery over the past month, inflammatory bowel disease * Presence of diabetes (type I \& type II) or diseases causing significant nutritional status impairment (malignancy, chronic infections) * Patients who have changed their disease modifying drugs in the past 6 months prior to study * Impaired cognition that limited ability to complete the questionnaires. Addiction to drugs or alcohol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple sclerosis (MS) - relapsing-remitting are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Depression Fatigue relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple sclerosis (MS) - relapsing-remitting

Contacts and locations

Locations

  • Faculty of medicine

    Cairo, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.